TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.5% during the 4th quarter, Holdings Channel reports. The firm owned 830,184 shares of the biopharmaceutical company’s stock after purchasing an additional 57,996 shares during the period. Principal Financial Group Inc.’s holdings in TG Therapeutics were worth $24,989,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TGTX. State Street Corp grew its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of TG Therapeutics by 0.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock valued at $27,708,000 after buying an additional 7,939 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Barclays PLC grew its holdings in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares in the last quarter. Finally, Castellan Group purchased a new position in shares of TG Therapeutics during the fourth quarter valued at $8,539,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TGTX. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 0.2 %

Shares of TGTX opened at $30.88 on Monday. TG Therapeutics, Inc. has a 12-month low of $12.90 and a 12-month high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $4.81 billion, a price-to-earnings ratio of -308.77 and a beta of 2.26. The stock’s 50-day moving average price is $31.07 and its 200 day moving average price is $27.84.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.